Herpes Zoster in Patients Treated with Biologicals

Failla, Valérie; Jacques, Jessica; Castronovo, Charlotte; Nikkels, Arjen F.

doi:10.1159/000338691

Cited by 34 publications

(36 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VZV infection in IBD patients treated with IFX is described in several patients in Table 4 (212)(213)(214)(215)(216)(217)(218)(219)(220). The risk of herpes zoster was assessed in anti-TNF patients in the French research axed on tolerance of biotherapies registry.…”

Section: Varicella Zoster Virusmentioning

confidence: 99%

“…Herpes zoster is described in several cases comprising both pediatric and adult patients (213)(214)(215)(216)(217)(218). IFX [incidence rate (IR) 2.4 per 1000 patientyears, 95% CI 0.0-4.7] and ADM (IR 7.1 per 1000 patient-years, 95% CI 2.9-11.3) were associated with herpes zoster in a large Belgian cohort of patients treated with biologicals (216).…”

Section: Varicella Zoster Virusmentioning

confidence: 99%

“…IFX [incidence rate (IR) 2.4 per 1000 patientyears, 95% CI 0.0-4.7] and ADM (IR 7.1 per 1000 patient-years, 95% CI 2.9-11.3) were associated with herpes zoster in a large Belgian cohort of patients treated with biologicals (216). Herpes zoster occurred at the site of IFX infusion in a CD patient with a history of childhood varicella, manifesting as erythematous pruritic papulovesicles.…”

Section: Varicella Zoster Virusmentioning

confidence: 99%

“…These can be further accompanied by fever, nausea, headache and pain (216,218). A papular rash along the thoracic dermatome characteristic of herpes zoster occurred in a CD patient treated with IFX who developed a severe CMV infection (207).…”

Section: Varicella Zoster Virusmentioning

confidence: 99%

See 3 more Smart Citations

Risk of Infections of Biological Therapies with Accent on Inflammatory Bowel Disease

2014

View full text Add to dashboard Cite

Background: Biological therapies using anti-tumor necrosis factor (TNF)-α agents have an important impact in the treatment of inflammatory bowel disease, rheumatoid arthritis, psoriasis, and other inflammatory conditions. However, a significant number of patients lose their response to these medications over time. Clinical trials have demonstrated that antibodies against anti-TNF agents may impact treatment response and increase the risk of infusion reactions. Of concern is also the possibility of developing adverse events induced by anti-TNF agents. The purpose of the present systematic review is to describe the current knowledge on the risk of infections associated with anti-TNF agents antagonists, as well as integrin antagonists. We also intend to describe case reports of these adverse events in inflammatory bowel disease patients. Methods: Currently approved anti-TNF biologicals in IBD include the monoclonal antibodies infliximab, adalimumab, certolizumab pegol and golimumab. Integrin antagonists include natalizumab, etrolizumab and vedolizumab. Results: The most frequently-reported adverse events of these biologicals were infections, and these are described in detail in this study. Discussion: Most adverse events are due to the failure of host immunological control, which involves de novo infection, or reactivation of latent bacterial or viral infection, often with a different expression of disease. Conclusion: Risk assessment in individuals undergoing treatment with biologicals represents a step towards achieving treatment personalization to identify those patients that will safely benefit from this therapeutic approach. Patients and physicians must be alert for anti-TNF agents and anti-integrin medication as potential causes of drug-induced infections and monitor the therapies. Personalizing therapeutic vigilance promises to optimize benefits while minimizing infections.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

show abstract

Section: Varicella Zoster Virusmentioning

confidence: 99%

Section: Varicella Zoster Virusmentioning

confidence: 99%

Section: Varicella Zoster Virusmentioning

confidence: 99%

Section: Varicella Zoster Virusmentioning

confidence: 99%

See 2 more Smart Citations

Risk of Infections of Biological Therapies with Accent on Inflammatory Bowel Disease

2014

View full text Add to dashboard Cite

show abstract

“…Lis-Swiety ve ark ise rituksimab tedavisi alan romatoid artritli bir olguda gelişen subakut lupus eritematosusun rituksimabla iliş-kili olabileceğini ileri sürmüştür (20). Rituksimabın herpes zoster geliştirme riski üzerine yapılan bir çalışmada 1/168 sıklıkta neden olabileceği Failla ve ark tarafından tespit edilmiştir (21). Rituksimabın gebelik kategorisi C olup, potansiyel yararı çok güçlü olmadıkça fetüse yan etkileri açısından gebelikte kullanımından kaçın-mak gerekmektedir.…”

Section: Kutanöz Yan Etkilerunclassified